As we did not find significant differences in inflammatory markers, RA activity, bone erosion prevalence, RA treatment regimens, RF- and ACPA-positivity, the observed increased IMT and prevalence of plaque can be solely attributed to DM and the associated metabolic abnormalities. Here, PRTN3 is linked to rheumatoid arthritis.